Investor Overview

Webcast ImageWebcast
Histogenics Corp at the Canaccord Genuity 2018 Musculoskeletal Conference (Live)
03/06/18 at 9:00 a.m. ET
Histogenics Corp at the Canaccord Genuity 2018 Musculoskeletal Conference
Tuesday, March 6, 2018 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Histogenics Corp at the Cowen and Company 38th Annual Health Care Conference (Live)
03/14/18 at 8:40 a.m. ET
Histogenics Corp at the Cowen and Company 38th Annual Health Care Conference
Wednesday, March 14, 2018 8:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.53
Change (%) Stock is Down 0.06 (2.32%)
Volume2,210
Data as of 02/23/18 10:29 a.m. ET
Minimum 20 minute delay
Refresh quote

Recent NewsMore >>
DateTitle 
02/20/18Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.  Canaccord Genuity 2018 Musculoskeletal Conference – New Orleans (March 6, 2018) Adam Gridley, Histogenics’ CEO, will present a corporate overview on Tuesday, Marc... 
Printer Friendly Version
01/25/18Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The total net proceeds of the offering are approximately $5.... 
Printer Friendly Version
01/22/18Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
WALTHAM, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten registered direct offering of 2,340,430 shares of its common stock at a price of $2.35 per share. In connection with the offering, Histogenics granted the underwriter a 30-day option to purchase up to an additional 351,064 shares of common stock. All of the shares in the offering are bein... 
Printer Friendly Version
01/09/18Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
WALTHAM, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that it has received the $10 million up-front payment from MEDINET Co., Ltd. (MEDINET), under the previously announced agreement for the development and commercialization of NeoCart® for the Japanese market.  Per the terms of the agreement, the up-front payment was... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
03/06/18 9:00 a.m. ET
Histogenics Corp at the Canaccord Genuity 2018 Musculoskeletal Conference
03/14/18 8:40 a.m. ET
Histogenics Corp at the Cowen and Company 38th Annual Health Care Conference
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.